|        About Good Returns  |  Advertise  |  Contact Us  |  Terms & Conditions  |  RSS Feeds

NZ's Financial Adviser News Centre

GR Logo
Last Article Uploaded: Friday, June 14th, 6:57PM


Latest Headlines

Positive treatment signs for type 2 diabetes sufferers

AIA funds drug trial for people suffering from type 2 diabetes.

Thursday, March 16th 2023, 11:36AM

A lifestyle medicine programme aimed at improving health outcomes for those impacted by type 2 diabetes has achieved significant positive results. Lifestyle medicine uses evidence-based therapeutic lifestyle interventions to treat chronic conditions.

The programme, which was developed by PREKURE, an organisation focused on preventative lifestyle medicine, found 100% of participants who elected to share data in a 12-week trial achieved reduced blood sugar levels through its diabetes programme and half achieved a clinically significant reduction in their blood sugar levels.

The trial, funded by AIA, was for a group of its customers managing type 2 diabetes, or who are pre-diabetic.

PREKURE chief science officer, Grant Schofield, says diabetes diagnoses are on the rise, putting a strain on New Zealand’s healthcare system, but that diet and lifestyle changes can achieve significant health improvements.

“Approximately one in 20 New Zealanders have been diagnosed with type 2 diabetes. By 2040, this is projected to almost double to one in 10. This is undoubtedly going to impose a huge burden both on our health system and Kiwi families.

“But it doesn’t have to be that way. PREKURE is centred on disease prevention through lifestyle medicine. The 12-week trial equipped the participants with achievable diet changes, one-on-one health coaching, and group health coaching sessions to keep them focused and on track towards their goals,” Schofield says.

“Seeing all participants report a reduced blood sugar level, which is a key diabetes indicator, compared to when they started the trial was incredible. Participants also lost an average of 5kgs in excess body weight throughout the trial, which was another fantastic outcome, demonstrating the dedication they had to the programme.

“Crucially, all those who participated in the trial are now better equipped to self-manage their diabetes or help reverse their pre-diabetes diagnosis altogether.”

AIA chief product and investments officer, Len Elikhis, found the programme’s results and the real-world impacts the PREKURE programme had on participants’ lives inspiring.

“We’re proud to support a programme which is really making a difference. We’ve already witnessed the transformative effect it’s having on the lives of everyday New Zealanders,” Elikhis says.

“For many participants, the programme was life changing. Hearing that you are pre-diabetic or being diagnosed with type 2 diabetes is a huge wake-up call for many. Fortunately, there is strong international evidence that metabolic conditions, like diabetes, can be improved or reversed through nutrition.

Tags: AIA

« Fidelity gets acting CEO for six monthsTick box adviser declaration coming »

Special Offers

Comments from our readers

No comments yet

Sign In to add your comment



Printable version  


Email to a friend
Insurance Briefs

New customers get 3-months' premium-free on Fidelity Life
Fidelity Life has announced a special offer to cover new customers’ premiums for the first 3-months of their policies.

Premium relief for customers in drought areas
Fidelity Life offers premium relief to drought-affected customers

Fidelity Life relaunches customer engagement initiative
Once again Fidelity Life wants to recognise advisers who go above and beyond to deliver amazing customer service.

Asteron Life unveils product enhancements
Asteron Life is proud to announce a series of enhancements and clarifications to multiple covers across Personal and Business Insurance product offerings, reflecting its commitment to understanding and meeting the evolving needs of customers, and making it a more seamless experience for advisers.

News Bites
Latest Comments
Subscribe Now

Cover Notes - Specific news aimed at risk advisers

Previous News
Most Commented On
About Us  |  Advertise  |  Contact Us  |  Terms & Conditions  |  Privacy Policy  |  RSS Feeds  |  Letters  |  Archive  |  Toolbox  |  Disclaimer
Site by Web Developer and